CompletedNot Applicable

Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve)

Germany90 participantsStarted 2010-12

Plain-language summary

Aim is to validate that non-invasive brain stimulation can increase cortical excitability in the visual system. The investigators assess if transcranial alternating current stimulation (tACS) can improve visual field size in patients with optic nerve damage. Hypothesis: tACS would improve visual functions within the defective visual field (primary outcome measure).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with optic nerve lesion * stable visual field defect with residual vision * lesion age at least 6 months * age at least 18 years * no completely blindness, residual vision still existent Exclusion Criteria: * electric or electronic implants, e.g. heart pacemaker * any metal artefacts in head and truncus * epilepsy * auto-immune diseases in acute stage * mental diseases, e.g. schizophrenia etc. * unstable diabetes, diabetes causing diabetic retinopathy * addiction * high blood pressure (max. 160/100 mmHg) * instable or high level of intraocular pressure (i.e. \> 27 mmHg) * retinitis pigmentosa * pathological nystagmus * presence of an un-operated tumor anywhere in the body * pregnant or breast-feeding women * photo sensibility * Fundus hypertonicus * acute conjunctivitis

What they're measuring

Detection accuracy (DA) change in percent over baseline within defective visual field

Timeframe: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course

Trial details

NCT IDNCT01280877

SponsorUniversity of Magdeburg

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-02

View on ClinicalTrials.gov More Optic Nerve Diseases trials